MX2023014719A - Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer. - Google Patents

Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2023014719A
MX2023014719A MX2023014719A MX2023014719A MX2023014719A MX 2023014719 A MX2023014719 A MX 2023014719A MX 2023014719 A MX2023014719 A MX 2023014719A MX 2023014719 A MX2023014719 A MX 2023014719A MX 2023014719 A MX2023014719 A MX 2023014719A
Authority
MX
Mexico
Prior art keywords
disease
alzheimer
treatment
neuroactive steroid
cyp46a1
Prior art date
Application number
MX2023014719A
Other languages
English (en)
Spanish (es)
Inventor
Albert Jean Robichaud
Michael C Quirk
James J Doherty
Aaron Michael Koenig
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023014719A publication Critical patent/MX2023014719A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023014719A 2021-06-11 2022-06-10 Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer. MX2023014719A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163209929P 2021-06-11 2021-06-11
US202163289081P 2021-12-13 2021-12-13
US202263321598P 2022-03-18 2022-03-18
PCT/US2022/033122 WO2022261510A1 (en) 2021-06-11 2022-06-10 Neuroactive steroid for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2023014719A true MX2023014719A (es) 2024-02-15

Family

ID=82361350

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014719A MX2023014719A (es) 2021-06-11 2022-06-10 Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer.

Country Status (9)

Country Link
US (1) US20250319105A1 (https=)
EP (1) EP4351588A1 (https=)
JP (1) JP2024520805A (https=)
KR (1) KR20240035444A (https=)
AU (1) AU2022291395A1 (https=)
CA (1) CA3223179A1 (https=)
IL (1) IL309208A (https=)
MX (1) MX2023014719A (https=)
WO (1) WO2022261510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4704905A1 (en) * 2023-05-02 2026-03-11 Sage Therapeutics, LLC Lymphatic system-targeting compounds
TW202508603A (zh) * 2023-05-02 2025-03-01 美商賽吉醫療公司 神經活性類固醇調配物及其使用方法
WO2025021195A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025020191A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AP2014007606A0 (en) 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
JP6272833B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
EP3102230B1 (en) * 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
US10562881B2 (en) 2015-10-16 2020-02-18 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
CA3021634A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CA3038984A1 (en) 2016-09-30 2018-04-05 Schlumberger Canada Limited Fiber measurements for fluid treatment processes in a well
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
WO2022115620A1 (en) 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
WO2022261510A1 (en) 2022-12-15
KR20240035444A (ko) 2024-03-15
JP2024520805A (ja) 2024-05-24
IL309208A (en) 2024-02-01
US20250319105A1 (en) 2025-10-16
CA3223179A1 (en) 2022-12-15
EP4351588A1 (en) 2024-04-17
AU2022291395A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
MX2023014719A (es) Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer.
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CO2022017072A2 (es) Imidazopiridazinas como moduladores de il-17
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
CO2026004964A2 (es) Moduladores de kras
MX2021008518A (es) Compuestos que modulan fxr(nr1h4).
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CL2024002767A1 (es) Moduladores de nlrp3
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BRPI0511569A (pt) composições e métodos para o tratamento de distúrbio disfórico pré-menstrual
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR112022021640A2 (pt) Usos e formulações de canabinoides
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112022003768A2 (pt) Compostos inibidores de perk
BR112022001395A2 (pt) Métodos para administrar anticorpos anti-siglec-8 e corticosteroides
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca